mTORC1
Complex in Homo sapiens that 1 drug acts on.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
- Genes: 3
Who is on it, and how far along
Every drug ChEMBL records acting on MLST8, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Indoximod | Phase 2 | Lumos Pharma | Small molecule | ActivatormTORC1 activator | 3 |
| Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer | Indoximod | Phase 1 | Not yet recruiting | Lumos Pharma | Jul 28, 2026 |
| Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | Indoximod | Phase 1 | Recruiting | Theodore S. Johnson | Nov 3, 2021 |
| Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG | Indoximod | Phase 2 | Active, not recruiting | Theodore S. Johnson | Aug 8, 2019 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4296661, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets